A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

New England Journal of Medicine

Volumn 349, Issue 14, 2003, Pages 1341-1348

  Klugman, Keith P ^a,b,e   Madhi, Shabir A ^a   Huebner, Robin E ^a   Kohberger, Robert ^c   Mbelle, Nontombi ^a   Pierce, Nathaniel ^d  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b EMORY UNIVERSITY   (United States)

^c PFIZER INC   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DIPHTHERIA TOXIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC RESISTANCE; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION RISK; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; RESPIRATORY TRACT INFECTION; SEIZURE; SOUTH AFRICA; STRAIN DIFFERENCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

DOUBLE-BLIND METHOD; DRUG RESISTANCE, BACTERIAL; FEMALE; HAEMOPHILUS VACCINES; HIV INFECTIONS; HUMANS; INCIDENCE; INFANT; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; POLYSACCHARIDES, BACTERIAL; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 0141430931     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa035060     Document Type: Article

References (26)

1. Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2002;2:25-32.
2. Mulholland K. Strategies for the control of pneumococcal diseases. Vaccine 1999;17: Suppl 1:S79-S84.
3. Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990;3:171-96.
4. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence ofmultidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;343:1917-24.
5. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187-95.
6. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use. Clin Infect Dis 2000;30:100-21.
7. Madhi SA, Cumin E, Klugman KP. Defining the potential impact of conjugate bacterial polysaccharide-protein vaccines in reducing the burden of pneumonia in human immunodeficiency virus type 1-infected and -uninfected children. Pediatr Infect Dis J 2002;21:393-9.
8. Performance standards for antimicrobial susceptibility testing: twelfth international supplement. M100-S12. Wayne, Pa.: National Committee for Clinical Laboratory Standards, 2002.
9. Madhi SA, Schoub B, Simmank K, Blackbum N, Klugman KP. Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J Pediatr 2000;137:78-84.
10. Pneumonia Vaccine Trial Investigators' Group. Standardization of interpretation of chest radiographs for the diagnosis of pneumonia in children. Geneva: World Health Organization, 2001. (WHO/V & B/01.35.)(WHOIV& B/01.35.)
11. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age: official authorized addenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting ICD-9-CM. MMWR Morb Mortal Wkly Rep 1994;43(RR-12):1-19.
12. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 2. The design and analysis of cohort studies. Lyons, France: International Agency for Research on Cancer, 1987. (IARC scientific publications no. 82.)
13. Mbelle N, Huebner RE, Wasas AD, Kimura A, Chang I, Klugman KP. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999;180:1171-6.
14. Huebner RE, Mbelle N, Forrest B, Madore DV, Klugman KP. Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa. Pediatr Infect Dis J 2002;21:1004-7.
15. Santosham M. Invasive disease efficacy of a 7-valent pneumococcal conjugate vaccine among Navajo and White Mountain Apache (N/WMA) children. Int J Tuberc Lung Dis 2001;5:Suppl 1:S27. abstract.
16. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, Morb Mortal Wkly Rep 2000;49(RR-9):1-35.
17. Madhi SA, Petersen K, Madhi A, Khoosal M, Klugman KP. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clin Infect Dis 2000;31:170-6.
18. French N, Nakiyingi J, Carpenter LM, et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000;355:2106-11.
19. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002;21:810-5.
20. Mulholland K, Hilton S, Adegbola R, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine for prevention ofpneumonia and meningitis in Gambian infants. Lancet 1997;349:1191-7. [Erratum, Lancet 1997;350:524.]
21. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-46.
22. Dagan R, Melamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996;174:1271-8.
23. Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 2002;35:547-55.
24. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. N Engl J Med 2000;342:681-9.
25. DeStefano F, Gu D, Kramarz P, et al. Childhood vaccinations and risk of asthma. Pediatr Infect Dis J 2002;21:498-504.
26. von Hertzen LC. Puzzling associations between childhood infections and the later occurrence of asthma and atopy. Ann Med 2000;32:397-400.